AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
- ACI-125891 delivers the first element of a precision medicine approach by enabling early and accurate diagnosis of a-synpathology in certain diseases
- Clinical trial of ACI-12589 showed a specific and reproducible retention pattern in patients with MSA, a rare and difficult-to-diagnose neurodegenerative disease
- ACI-12589 promises to catalyze accelerated development and targeted treatment of MSA and other a-synucleinopathies such as genetic Parkinson’s disease (PD)
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the publication of a peer-reviewed paper in Nature Communications showing the ability of an alpha-synuclein (a-syn) positron emission tomography (PET) tracer to identify patients with multiple system atrophy (MSA).